Our data suggest that the cytotoxic effects of NAMPT inhibitors are, in part, independent of IDH1 status, thus possibly limiting their suitability as a selective treatment option for IDH1 mutated glioma. The gene discussed is IDH1; the disease is central nervous system cancer.